Press Release: Viriom : Viriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral Formulation
SAN DIEGO, Dec. 3, 2019 /PRNewswire/ -- Viriom Inc (Viriom) announces launching Segment I and Segment II reproductive toxicity studies of Elpida® (elsulfavirine) HIV-1 therapy, supported by preclinical services of the...
Read full article »
Viriom is a biotech company that develops and commercializes novel therapies for the treatment of life threatening infections such as HIV and HBV.
Read more